Research & Clinical Interest
1. Barbari A. Posttransplant Hypertension: Multipathogenic Disease Process. Experimental Clinical Transplantation April 2013. In press 2. Barbari A, Abbas S, and Jaafar M. Approach to kidney Transplantation in Sensitized Potential Transplant Recipients. Experimental Clinical Transplantation 2012; (5) : 419-427 3. The Declaration of Istanbul on organ trafficking and transplant tourism. International Summit on Transplant Tourism and Organ Trafficking. Saudi J Kidney Dis Transpl. 2010 Jan;21(1):138- 47 4. The Declaration of Istanbul on organ trafficking and transplant tourism. International Summit on Transplant Tourism and Organ Trafficking. Kidney Int. 2008 Oct;74(7):854-9. 5. Organ trafficking and transplant tourism and commercialism: The Declaration of Istanbul. Lancet, July 2008, 372:5-6. 6. The Declaration of Istanbul on Organ Trafficking and Transplant Tourism. Nephrol Dial Transplant. 2008 Nov;23(11):3375-80. 7. Barbari A, Masri M, Stephan A, Rizk S, Younan F, Bassil N. Time average Cyclosporine maximum level in stable De novo kidney transplant patients: Two years follow-up. Experimental Clinical Transplantation, November 2008, Abstract P 161. 8. Barbari A. Drug lymphocyte level: New perspective in clinical immunosuppression monitoring. Annals of Transplantation, September 2008, Abstract P 45 9. Chammas E, Hussein A, Barbari A, Abou Akl M, Hamoui O, Abouzahr L. Regression of cardiac lupus under immunosuppressive therapy. Circulation 2008; World Congress of Cardiology, May 2008, Abstract P1349. 10. Stephan A, Barbari A, Younan F. Ethical aspects on organ donation. Experimental Clinical Transplantation 2007; 2: 633-637.
11. Masri M, Rizk S, Barbari A, Stephan A, Kamel G, M Rost. An assay for the determination of Sirolimus levels in the lymphocyte of transplant patients. Transplant Proc May 2007; 39 (4):1204-12 12. Barbari A, Stephan A and Masri M. Calcineurin inhibitors-free immunosuppression: Risks and benefits. Saudi J Kid Dis Transplant March 2007; 18(1